UKPDS Legacy Study
OVERVIEW
UKPDS was a randomised, multicentre trial of glucose-lowering and antihypertensive therapies in patients with newly diagnosed type 2 diabetes. The study showed that complications of diabetes could be reduced by more intensive blood glucose and/or blood pressure control using existing treatments and dramatically changed the management of type 2 diabetes worldwide.
The UKPDS Legacy Study is an extended follow-up of UKPDS using electronic health records and other routinely collected health data.
DESIGN
The UKPDS Legacy Study intends to obtain updated forty-year follow-up data for the original participants of the UKPDS study by accessing electronic health record data via NHS Digital and NHS Scotland.
AIMS
To investigate whether early more intensive blood glucose and/or blood pressure control is associated with:
- A reduction in the risk of dementia
- A reduced risk of major vascular disease in the longer term
To assess the health economic impact of early more intensive blood glucose and/or blood pressure control over a lifetime horizon
FURTHER INFORMATION
If you were a UKPDS participant, you can read the privacy notice for the UKPDS Legacy study here.
| Chief investigator | Rury Holman |
| Co-investigators | William Whiteley Alastair Gray Jose Leal Ruth Coleman |
| Sponsor | University of Oxford |
| Funder | Diabetes Trials Unit, University of Oxford Chief Scientist’s Office, Scotland |
| Reference number | IRAS: 249166 |
Latest News
Intensive blood glucose control for people with type 2 diabetes when they are first diagnosed reduces diabetic complications and prolongs life
21 September 2022
The study, which tracked volunteers for up to 44 years, showed that the benefits of early intensive blood glucose control can persist for decades.